← Back to Clinical Trials
Recruiting NCT05860894

NCT05860894 Post Intensive Care Unit Atrial Fibrillation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05860894
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire de Besancon
Condition Atrial Fibrillation
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2023-09-19
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Implantable ECG holter device (Biomonitor3, Biotronik)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 150 participants in total. It began in 2023-09-19 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Atrial fibrillation (AF) is a common heart rhythm disorder in the intensive care unit (ICU). It can be precipitated by multiple factors but it is unclear whether AF persists after discharge from the ICU, and long term. This study will investigate whether AF recurs up to one year after ICU discharge.

Eligibility Criteria

Inclusion Criteria: * Age \>18 years * New onset atrial fibrillation diagnosed in the ICU (12 lead ECG or documented episode of atrial fibrillation lasting at least 30 seconds) * Patient hospitalized in the ICU with at least one of the following two criteria: * orotracheal intubation for mechanical ventilation * AND/OR treatment with amines (vasopressors or inotropic agents) * Written informed consent * Patient affiliated to a social security regime (or beneficiary thereof) Exclusion Criteria: * Documented history of atrial fibrillation * patients admitted to the ICU after cardiothoracic surgery * Patients with life expectancy \<12 months * Patients under legal or judicial protection * Patients with no social security coverage * Patients within the exclusion period of another clinical trial

Contact & Investigator

Central Contact

Charles Monnin, MD

✉ charles.monnin@edu.univ-fcomte.fr

📞 33381668186

Frequently Asked Questions

Who can join the NCT05860894 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05860894 currently recruiting?

Yes, NCT05860894 is actively recruiting participants. Contact the research team at charles.monnin@edu.univ-fcomte.fr for enrollment information.

Where is the NCT05860894 trial being conducted?

This trial is being conducted at Besançon, France.

Who is sponsoring the NCT05860894 clinical trial?

NCT05860894 is sponsored by Centre Hospitalier Universitaire de Besancon. The trial plans to enroll 150 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology